Hologic Tops Estimates - Analyst Blog
January 31 2012 - 5:30AM
Zacks
Hologic (HOLX)
reported an adjusted EPS of 34 cents during the first quarter of
fiscal 2012, a couple of cents above the Zacks Consensus Estimate
and 4 cents above the year-ago figure. Revenues were $472.7
million, an increase of 9.3% year over year and higher than the
Zacks Consensus Estimate of $466 million.
Segments
Hologic operates through four
segments − Breast Health, Diagnostics, GYN (Gynecology) Surgical
and Skeletal Health − each contributing a corresponding 46%, 33%,
16% and 5% to total revenue during the quarter. These segments
recorded robust growth of 10.2% year over year (at $215.4 million),
10.8% ($154.1 million), 3.8% ($78.5 million) and 10.3% ($24.7
million), respectively.
The upside at the Breast Health
segment was driven by a 10.9% increase in product revenue and a 9%
rise in service revenue related to Hologic’s increased installed
base of digital mammography systems. Product revenue growth was
driven by shift in sales from Selenia to Dimensions, stronger sales
of breast biopsy products led by Eviva and to a lesser extent an
increase in the total number of digital mammography systems
sold.
Growth at the Diagnostic segment
was driven by increased revenues from both Cervista HPV and
ThinPrep. Besides, incremental ThinPrep revenue from the TCT
acquisition was $7.3 million during the reported quarter.
The marginal increase in GYN
Surgical revenues was primarily due to inclusion of MyoSure
revenues, partially offset by lower sales of NovaSure system.
However, on a sequential basis, NovaSure system sales increased by
5%. The increase in Skeletal Health revenues emanated from higher
sales of bone densitometry units.
In the recent past, Hologic has
received some significant product approvals. These include approval
from US Food and Drug Administration for the Cervista High
Throughput Automation (HTA) system for HPV Screening. The company
also received CE Mark approval for C-View synthesized 2D image
reconstruction algorithm for 3D mammography exams and a nod in
China for the Serenity digital mammography system.
Guidance
Hologic provided its guidance for
the second quarter of fiscal 2012. For the said quarter, the
company expects to report $470−$475 million of revenues
(representing annualized growth of 7−8%) resulting in adjusted EPS
of 33 cents, in line with the Zacks Consensus EPS Estimate. The
current Zacks Consensus revenue estimate stands at $471 million.
For fiscal 2012, Hologic still expects to report revenues of
$1.9−$1.925 billion (growth of 6−8%) while the adjusted EPS
guidance was raised by a penny at both ends to $1.36−$1.38.
Recommendation
Offering a wide range of products,
Hologic has become an industry giant in the field of women’s health
products. Moreover, the company is also undertaking several steps,
including acquisitions, international expansion and product
development to bolster its top line. We are encouraged by the
recent product approvals, which should help the company in
recording higher sales going forward.
However, the company continues to
be affected by lower visits to physicians due to the prevailing
economic uncertainty. The growth reflected in the company’s
guidance is primarily based on the acquisitions made in 2011.
Hologic also witnesses tough competition from players like
Qiagen (QGEN) and Conceptus
(CPTS), among others. The stock retains a Zacks #3 Rank (“Hold”) in
the short term. Over the long term, we are Neutral on Hologic.
CONCEPTUS INC (CPTS): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
QIAGEN NV (QGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jul 2023 to Jul 2024